These findings suggest a new role for mTORC1–SRPK2 signaling in the posttranscriptional regulation of lipid metabolism and highlight SRPK2 as a promising therapeutic target for metabolic disorders driven by mTORC1. Here, SRPK2 is linked to metabolic disease.